七国特应性湿疹注册库入组患者基线特征分析
TREAT注册工作组汇总七个欧洲观察性队列,纳入5337例特应性湿疹患者。基线时84.1%曾用系统治疗,75.0%正用度普利尤单抗;平均EASI 17.6分,41.9%为中度、30.1%为重度,POEM平均17.2分、DLQI平均13.4分、瘙痒NRS 6.4。
要点
- 入组患者以成人为主(平均39.1岁),54.4%为男性,儿童占6.3%。
- 84.1%既往接受过系统治疗,最常见为系统糖皮质激素(58.8%)和环孢素(39.0%)。
- 入组时度普利尤单抗处方率最高(75.0%),环孢素7.8%、JAK抑制剂5.9%、光疗1.7%。
核心结论
- 七国注册库汇总显示患者基线疾病负担重且系统治疗使用普遍,为后续疗效与安全性分析奠定基础。
研究设计与样本
- 共纳入5337例特应性湿疹患者,平均年龄39.1岁,儿童占6.3%,男性占54.4%。
主要发现
- 84.1%既往接受过系统治疗,其中系统糖皮质激素58.8%、环孢素39.0%,30.1%曾接受光疗。
- 入组时度普利尤单抗处方率75.0%,环孢素7.8%,JAK抑制剂5.9%,光疗1.7%。
- 基线41.9%为中度、30.1%为重度,平均EASI 17.6分,POEM平均17.2分。
- DLQI平均13.4分,瘙痒NRS平均6.4分。
临床怎么用
- 提示欧洲真实世界中生物制剂已成为中重度特应性湿疹的主要系统治疗选择。
- 基线EASI、POEM、DLQI和瘙痒NRS可作为后续疗效评价的参照。
局限性
- 各注册库数据收集存在差异,可能影响汇总结果的同质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The TREAT Registry Taskforce is a collaborative effort of international registries aiming to provide real-world data on the long-term efficacy, cost-effectiveness and safety of systemic treatments and phototherapy for atopic eczema (AE). OBJECTIVES: This study seeks to present a comprehensive overview of the demographics, prior systemic treatments, clinical characteristics and disease severity and burden at baseline among patients enrolled in seven TREAT registries. Moreover, the aim is to gain insight into the differences between the registries and to explore the current prescribing practices of various therapies for patients with AE across Europe. METHODS: Data from June 2016 to 31 October 2022, were collected from seven observational cohorts: A-STAR (UK/Ireland), AtopyReg (Italy), Biobadatop (Spain), SCRATCH (Denmark), SwedAD (Sweden), TREATgermany (Germany) and TREAT NL/BE (Netherlands/Belgium). RESULTS: The analysis included 5337 patients, with a mean age of 39.1 years (6.3% paediatric, 54.4% male). Of these, 84.1% had previously received systemic treatments, primarily systemic corticosteroids (58.8%) and ciclosporin (39.0%), while 30.1% had undergone phototherapy. At enrolment, dupilumab was the most prescribed treatment (75.0%), followed by ciclosporin (7.8%) and Janus Kinase inhibitors (5.9%); only 1.7% started phototherapy. Baseline assessments showed that most patients had moderate (41.9%) to severe (30.1%) AE, with an average Eczema Area and Severity Index (EASI) score of 17.6. The Patient-Oriented Eczema Measure (POEM) score averaged 17.2, indicating severe disease impact. The Dermatology Life Quality Index (DLQI) score averaged 13.4, and the Numerical Rating Scale (NRS) for itch was 6.4. CONCLUSIONS: This pooled analysis from the TREAT Registry Taskforce highlights the variability and similarities in data collection across national registries, providing significant insights into the baseline characteristics of the patient population. It establishes a robust foundation for future analyses of key effectiveness and safety outcomes.
引用
- Musters AH, Gerbens LAA, van der Gang L, et al. Baseline characteristics of atopic eczema patients enrolled in seven European registries united in the TREatment of ATopic eczema (TREAT) registry taskforce. J Eur Acad Dermatol Venereol. 2025. PMID: 40832875. doi:10.1111/jdv.20876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。